Amicus Therapeutics, Inc. (FOLD) Stock Rating Reaffirmed by Cowen and Company
Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating reaffirmed by Cowen and Company in a research note issued to investors on Tuesday.
The analysts wrote, “This morning, FOLD announced that after more recent FDA talks and written.””
Other analysts have also recently issued research reports about the company. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 16th. J P Morgan Chase & Co set a $13.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Monday, June 5th. Chardan Capital reiterated a “buy” rating and set a $12.50 target price on shares of Amicus Therapeutics in a research report on Thursday, June 1st. Bank of America Corporation cut their target price on Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, May 25th. Finally, Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 21st. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $11.46.
Amicus Therapeutics (NASDAQ:FOLD) traded up 25.83% on Tuesday, reaching $12.91. The company’s stock had a trading volume of 21,919,463 shares. The stock has a 50-day moving average of $8.63 and a 200-day moving average of $6.95. Amicus Therapeutics has a one year low of $4.41 and a one year high of $13.28. The stock’s market cap is $1.85 billion.
Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.02. The company had revenue of $4.20 million during the quarter, compared to analysts’ expectations of $4.16 million. Amicus Therapeutics’s revenue was up 50.0% on a year-over-year basis. On average, analysts predict that Amicus Therapeutics will post ($1.45) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Amicus Therapeutics, Inc. (FOLD) Stock Rating Reaffirmed by Cowen and Company” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/11/amicus-therapeutics-inc-fold-stock-rating-reaffirmed-by-cowen-and-company.html.
In other Amicus Therapeutics news, insider Hung Do sold 29,914 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the completion of the transaction, the insider now owns 474,438 shares in the company, valued at approximately $3,795,504. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jay Barth sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $10.00, for a total value of $300,000.00. Following the transaction, the insider now owns 64,184 shares of the company’s stock, valued at approximately $641,840. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Princeton Alpha Management LP purchased a new position in Amicus Therapeutics during the first quarter valued at $106,000. Dynamic Technology Lab Private Ltd purchased a new position in Amicus Therapeutics during the second quarter valued at $108,000. Creative Planning boosted its position in Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,900 shares in the last quarter. Rockefeller Financial Services Inc. purchased a new position in Amicus Therapeutics during the first quarter valued at $136,000. Finally, M&T Bank Corp purchased a new position in Amicus Therapeutics during the first quarter valued at $157,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.